Previous 10 | Next 10 |
NEW ORLEANS , June 14, 2019 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (NYSE: AMRX). ...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will participate at the following upcoming investor conferences: Goldman Sachs 40 th Annual Global Healthcare Conference at 2:00 p.m. PT (5:00 p.m. ET) on June 12, 2019 in Rancho Palos Verdes, CA. ...
CIRCOR (NYSE: CIR ) +51% on Crane buyout offer . More news on: CIRCOR International, Inc., JMU Limited, Biocept, Inc., Stocks on the move, Read more ...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (NYSE: AMRX). For many years, the Company, (formerly Impax ...
Endpoints News reports that Gilead Sciences ( GILD +1.6% ) CEO Daniel O'Day spent more than three hours yesterday trying to justify the $2,000/month price of Truvada (emtricitabine and tenofovir disoproxil fumarate) before a U.S. House committee on oversight and reform. The FDA approved ...
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) today announced that members of management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 21, 2019 at 11:00 a.m. Eastern Time. To access a live webcast of the presentation, v...
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2019 Earnings Conference Call May 09, 2019 8:30 AM ET Company Participants Mark Donohue – Vice President of Investor Relations and Corporate Communications Rob Stewart – President and Chief Executive Officer Todd Branning ...
Amneal Pharmaceuticals ( AMRX -16.1% ) Q1 results : Revenues: $446.1M (+62.1%). More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...